Pharmacodynamic effect of sequential #belimumab and #rituximab therapy in patients with systemic #lupus: BLISS-BELIEVE study #EULAR2022 >CR https://t.co/AgBBuqYatW

Alsing et al. Dutch study. Persistent excess stroke risk in RA in biologic era. @RheumNow #EULAR2022 OP0277 https://t.co/oLmsrniKw6 https://t.co/2zDkuUzq0S

• EULAR Abstract Archive

A new finding - antimalarials improve safety w bDMARDs & #JAKi and reduce CV events and improve drug survival #Bestinclass. POS0242 @RheumNow @eular_org #EULAR2022 Neat. Safe, inexpensive and monitor eyes 👀 https://t.co/Ea4VA9vqwe

BTKi are they effective in #rheumatology? Seem to work in preclinical models of inflammation but so far clinical results seem disappointing #POS0397 @RheumNow @eular_org #EULAR2022 https://t.co/2NjcMnU1d6

Swedish study by Lindstrom U et al of over 3000 PsA patients matched with RA comparators showed that the length of time on MTX (PsA 4.5 and RA 4.4 years) before adding or switching to b/tsDMARD was identical in PsA (34%) and matched RA controls (33%) #EULAR2022 @RheumNow POS0073 https://t.co/Dwrz8RVMnh

Dr Singh @NamrataRheum et al. VA study of lymphoma risk with b/tsDMARDs. No increased risk found. HR adjusted time-fixed and time-varying covariates vs csDMARD 1.04 (0.80-1.35) @RheumNow #EULAR2022 POS1434 https://t.co/B6ENz805yl